CLAIMS

1. ~~A method of treating female sexual dysfunction induced by one or more antidepressants, previously administered to a female subject, the method comprising applying topically~~ Use of a topical composition comprising cannabidiol (CBD) ~~("CBD-containing composition")~~ in the preparation of a medicament for treating female sexual dysfunction induced by one or more antidepressants, previously administered to a female subject, wherein: ~~said composition being applied~~the medicament is adapted for application to ~~the~~a mucosal surface of the female subject's genital (arousal) area(s)~~, wherein~~ and the ~~composition~~medicament is adapted for ~~applied~~application in ~~the~~an amount and for a period of time prior to a sexual activity ~~such that sexual dysfunction of the subject is ameliorated~~for ameliorating the sexual dysfunction during the sexual activity.

2. The ~~method~~use of claim 1, wherein said topical composition is formulated as a lotion, an ointment, a cream, a suspension, a paste, a gel, a balm, a tincture, an emulsion, or a serum~~, any one of which is applied to the female genitalia~~.

3. The ~~method~~use of claim 1, wherein the genital area includes genitalia with absorptive mucosa, comprising one or more of: ~~the~~ introitus, ~~the~~ vulva, ~~the~~ labia minora, ~~the~~ clitoris and ~~the~~ vaginal vault.

4. The ~~method~~use of claim 1, wherein the one or more antidepressant causing sexual dysfunction is selected from: an SSRI, an SNRI, a tricyclic antidepressant, and a tetracyclic depressant.

5. The ~~method~~use of claim~~s~~ 4, wherein:

a) the SSRI is selected from: sertraline, citalopram, fluoxetine, escitalopram, paroxetine, fluvoxamine, duloxetine, venlafaxine, and desvenlafaxine;

b)~~.~~ the SNRI is selected from: duloxetine, venlafaxine, desvenlafaxine, milnacipran, and levomilnacipran;

c) the tricyclic antidepressant is selected from: clomipramine, trimipramine, amitriptyline, desipramine, imipramine, lofepramine, doxepin, nortriptyline, amoxapine, and protriptyline; and/or

d) the tetracyclic antidepressant is selected from maprotiline and mirtazapine.

6. The ~~method~~use as in claim 1, wherein the female subject is human and has been diagnosed with one or more disorders or conditions selected from the group consisting of major depressive disorder (MDD), persistent depressive disorder or dysthymia, melancholic depression, anxiety disorder (e.g., generalized anxiety disorder (GAD) and social anxiety disorder (SAD)), attention-deficit hyperactivity disorder (ADHD), obsessive–compulsive disorder (OCD), bulimia nervosa (bulimia), panic disorder, premenstrual dysphoric disorder, menopause-associated vasomotor symptoms, fibromyalgia, neuropathic pain, post-traumatic stress disorder (PTSD), diabetic peripheral neuropathy (DPN), and chemotherapy-induced neuropathy.

7. The ~~method~~use of claim 1, wherein the female sexual dysfunction is characterized by one or more of the following characteristics: difficulty achieving arousal and/or insufficient lubrication, difficulty in achieving and maintaining engorgement, and difficulty in achieving and maintaining lubrication.

8. The ~~method~~use of claim 1, wherein the female sexual dysfunction is characterized by one or more of the following characteristics: difficulty achieving orgasm, low orgasm intensity, or anorgasmia.

9. The ~~method~~use of claim 1, wherein the female sexual dysfunction is characterized to lack of sexual desire or interest.

10. The ~~method~~use of claim 1, wherein the female subject is premenopausal.

11. The ~~method~~use of claim 1, wherein the female subject is post-menopausal.

12. The ~~method as in~~use of claim 1, wherein the female subject has ~~been~~ previously been treated with, but did not satisfactorily respond to, one or more of the following treatments: (1) change of the time the antidepressant medication is taken, (2) drug holidays, (3) decrease of the dose of the medication, (4) switching to or addition of mirtazapine, (5) switching to or addition of bupropion, (6) addition of phosphodiesterase inhibitors (e.g., vardenafil, avanafil, and udenafil), (~~9~~7) topical testosterone, (~~7~~8) amantadine, (~~8~~9) yohimbine, (~~9~~10) switching to or addition of trazodone, (~~10~~11) stimulants such as methylphenidate, (~~11~~12) behavioral therapy, (~~12~~13) dietary supplements, e.g., saffron, and (~~13~~14) acupuncture.

13. The ~~method as in~~use of claim 1, wherein the female subject is further treated with one or more of the following treatments: (1) change of the time the antidepressant medication is taken, (2) drug holidays, (3) decrease the dose of the medication, (4) switching to or addition of mirtazapine, (5) switching to or addition of bupropion, (6) addition of phosphodiesterase inhibitors (e.g., vardenafil, avanafil, and udenafil), (~~9~~7) topicaltestosterone, (~~7~~8) amantadine, (~~8~~9) yohimbine, (~~9~~10) switching to or addition of trazodone, (~~10~~11) stimulants such as methylphenidate, (~~11~~12) behavioral therapy, (~~12~~13) dietary supplements, e.g., saffron, and (~~13~~14) acupuncture.

~~15.~~14. The ~~method~~use of claim 1, wherein ~~the amelioration of~~ameliorating the sexual dysfunction is exhibited by one or both of the following parameters:

i.vaginal and clitoral smooth muscle relaxation; and

ii.increased vaginal and clitoral blood flow.

~~16.~~15. The ~~method~~use of claim 1, wherein ~~the amelioration of~~ameliorating the sexual dysfunction is exhibited by one or more of the following subjectively self-reported outcomes including:

~~iii.~~i. “increased lubrication/wetness during sexual activity”;

~~iv.~~ii. “reaching orgasm more often”;

~~v.~~iii. “greater ease or achieving orgasm”;

~~vi.~~iv. “being more satisfied”;

~~vii.~~v. “higher level of sexual desire”; and

~~viii.~~vi. “reduction in pain during sexual activity”.

~~17.~~16. The ~~method~~use of claim 1, wherein the total amount of CBD ~~applied~~comprising the topical composition is from 5 mg to 1,000 mg of CBD~~, preferably~~ 10-100 mg of CBD~~, more preferably,~~ or 20-40 mg of CBD.

~~18.~~17. The ~~method~~use of claim 1, wherein the ~~composition is applied~~period of time is 1-60 min prior to sexual activity~~, preferably,~~ 5-40 min prior to sexual activity~~, more preferably~~ or 15-20 min prior to sexual activity.

~~19.~~18. The ~~method~~use of claim 1, wherein the ~~CBD-containing composition is applied at~~period of time is 5-30 mins prior to the sexual activity.

~~20.~~19. The ~~method~~use of claim 1, where~~in is~~the CBD is hemp-derived and/or contains less than 0.3% THC by weight.

~~21.~~20. The ~~method~~use of claim 1, wherein the ~~CBD-containing~~topical composition is provided in a single- use container.

~~22.~~21. The ~~method~~use of claim 1, wherein the ~~CBD-containing~~topical composition further comprises preservative(s) and is provided in a multi-use container.

~~23.~~22. The ~~method~~use of claim 1, wherein the concentration of CBD comprising~~in~~ the composition is from 1 mg/mL to 40 mg/mL~~, preferably,~~ 5 mg/mL to 20 mg/mL~~, more preferably,~~ or 10 mg/mL.

~~24.~~23. The ~~method~~use of claim 1, wherein the subject is afflicted with a disorder selected from: (1) Sexual Interest/Arousal Disorder (SIAD); and (2) Female Orgasmic Disorder.

~~25.~~24. The ~~method~~use of claim ~~23~~21 for a duration of 3-6 months, wherein the subject~~, upon having been treated with the CBD- containing composition for 3-6 months,~~ reports arousal and or orgasmic improvements as measured by FSFI, wherein the improvement in sexual interest/arousal domain is by 1-2 points, and by 1-2 points in the orgasm domain of the FSFI.

~~26.~~25. The ~~method~~use of claim 1, wherein the off-set time following the application of the CBD- containing composition is 0.5-5 hrs, preferably, 1-3 hrs, more preferably 1-2 hrs.

~~27.~~26. The ~~method~~use of claim 1, wherein the topical composition further comprises a phosphodiesterase type 5 (PDE-5) inhibitor ~~(e.g., sildenafil, tadalafil, vardenafil, avanafil, udenafil) is added to the CBD-containing composition~~.

27. The use of claim 26, wherein the PDE-5 inhibitor is chosen from: sildenafil, tadalafil, vardenafil, avanafil and udenafil.

28. The ~~method~~use of claim 1, wherein the topical composition further comprises another direct smooth muscle relaxant ~~(prostaglandin E1, papaverine, minoxidil) is added to the CBD-containing composition~~.

29. The use of claim 28, wherein the direct smooth muscle relaxant is chosen from: prostaglandin E1, papaverine and minoxidil.

~~29.~~30. The ~~method~~use of claim 1, wherein the topical composition further comprises: a) an alpha-blocker (e.g., phentolamine); b) flibanserin and/or c) bremelanotide ~~is/are added to the CBD-containing composition.to augment sexual desire~~.

~~30.~~31. The ~~method as in~~use of claim 1, wherein the medicament further comprises ~~subject is additionally treated with a~~ PDE-5 inhibitor ~~which is~~adapted for being administrated orally, or topically ~~similarly to CBD- containing composition~~, before, concurrently, or after the ~~application of the CBD-containing~~topical composition.

~~31.~~32. The ~~method as in~~use of claim 1, wherein the female subject was previously treated with an anti-depressant that induced sexual dysfunction and has persistent sexual dysfunction despite discontinuation of the anti-depressant therapy.